Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

181. Implementation and fidelity of a participatory learning and action cycle intervention to prevent and control type 2 diabetes in rural Bangladesh. Full Text available with Trip Pro

Implementation and fidelity of a participatory learning and action cycle intervention to prevent and control type 2 diabetes in rural Bangladesh. There is an urgent need to address the growing type 2 diabetes disease burden. 20-30% of adults in rural areas of Bangladesh have intermediate hyperglycaemia and about 10% have diabetes. We report on the implementation and fidelity of a Participatory Learning and Action (PLA) intervention, evaluated through a three-arm cluster randomised controlled (...) trial which reduced the incidence of diabetes and intermediate hyperglycaemia in rural Bangladesh. PLA interventions have been effective in addressing population level health problems in low income country contexts, and therefore we sought to use this approach to engage communities to identify and address community barriers to prevention and control of type 2 diabetes.We used a mixed methods approach collecting quantitative data through field reports and qualitative data through observations

2019 Global health research and policy Controlled trial quality: uncertain

182. Efficacy of a Lupinus mutabilis Sweet snack as complement to conventional type 2 diabetes mellitus treatment. Full Text available with Trip Pro

Efficacy of a Lupinus mutabilis Sweet snack as complement to conventional type 2 diabetes mellitus treatment. Introduction: therapeutic lifestyles changes including frequent consumption of legumes have resulted in improved metabolic control and decreased blood pressure in type 2 diabetes-mellitus (T2DM) patients. Objective: this was a quasi-experimental-28-week crossover-study that assessed the effect of daily consumption of the legume Lupinus mutabilis (LM) on metabolic control of T2DM

2019 Nutricion hospitalaria Controlled trial quality: uncertain

183. Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial. (Abstract)

Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial. Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type 2 diabetes have not yet been (...) fully investigated.To compare 1-year clinical outcomes of iFR-guided or FFR-guided treatment in patients with and without diabetes in the Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization (DEFINE-FLAIR) trial.The DEFINE-FLAIR trial is a multicenter, international, randomized, double-blinded trial that randomly assigned 2492 patients in a 1:1 ratio to undergo either iFR-guided or FFR-guided coronary revascularization. Patients were eligible for trial inclusion

2019 JAMA cardiology Controlled trial quality: predicted high

184. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Full Text available with Trip Pro

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Abnormalities in lipid metabolism may contribute to the development and progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Fenofibrate induces early and reversible reduction in estimated glomerular filtration rate (eGFR), but it may have protective effects on microvascular complications of diabetes. We hypothesized that randomization to fenofibrate versus (...) placebo would be associated with beneficial long-term effects on kidney outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial participants.We conducted a post hoc analysis in the ACCORD Lipid Trial to examine the association of randomization to fenofibrate versus placebo with change in eGFR and with time-to-development of microalbuminuria, macroalbuminuria, CKD, and kidney failure.We analyzed 2636 participants in the fenofibrate arm and 2632 in the placebo arm. During

2019 Kidney international reports Controlled trial quality: predicted high

185. Liraglutide (Victoza) - type 2 diabetes

liraglutide, in the management of patients with type 2 diabetes, existed in the form of the LEAD-programme. This programme consisted of six phase III, randomised, controlled, parallel-group trials. The majority were multi-national, multi-centre trials with the exception of LEAD-3 and LEAD-4, which were both multi-centre trials conducted across two countries. All six trials followed similar methodologies with the primary efficacy endpoint being a measure of the change in Hb A1C . In LEAD-1 and LEAD-2 (...) Liraglutide (Victoza) - type 2 diabetes Cost-effectiveness of liraglutide (Victoza®) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding the cost-effectiveness of liraglutide (Victoza®). Following assessment of the applicant’s submission, the NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing

2019 Pediatric Endocrine Society

186. Ertugliflozin (Steglatro) - type 2 diabetes mellitus

Ertugliflozin (Steglatro) - type 2 diabetes mellitus 1 Published 14 January 2019 1 SMC2102 ertugliflozin 5mg, 15mg film-coated tablet (Steglatro®) Merck Sharp & Dohme 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission ertugliflozin (Steglatro ® ) is accepted (...) , therefore hypoglycaemia is unlikely. 6 Efficacy is dependent on renal function, and is reduced in patients with moderate renal impairment and likely to be absent in severe renal impairment. Ertugliflozin is formulated as an immediate-release tablet that is taken once daily. 1 Current UK guidance recommends that SGLT-2 inhibitors used as monotherapy be considered as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do

2019 Scottish Medicines Consortium

187. Semaglutide (Ozempic) - the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise

Semaglutide (Ozempic) - the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise 1 Published 14 January 2019 1 SMC2092 semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic®) Novo Nordisk Ltd. 9 November 2018 (Issued 7 December 2018) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its (...) with type 2 diabetes (T2DM), the postprandial rise in endogenous GLP-1 is reduced or absent. GLP-1 receptor agonists can supplement or replace this deficiency. The submitting company has requested that SMC considers semaglutide when positioned for use in line with the current use of other GLP-1 receptor agonists, in addition to other medicinal products for the treatment of diabetes (i.e. as an add-on therapy to oral anti-diabetic drugs [OADs] or basal insulin). 3 The Semaglutide Unabated Sustainability

2019 Scottish Medicines Consortium

188. Type 2 diabetes: what's next after metformin?

300 IU/mL (Gla-300) solution is another option for adults with type 1 or type 2 diabetes requiring a long-acting basal insulin. Gla-300 is a concentrated formulation of the PBS-listed Gla-100. MedicineWise News: Type 2 diabetes – when metformin is not enough Sulfonylureas are the usual add-on treatment when metformin is no longer sufficient, but are they the best? Review the evidence on efficacy, safety and outcomes for second-line type 2 diabetes treatments. NPS RADAR: Pharmacological therapies (...) of first choice for people with type 2 diabetes who have inadequate glycaemic control after 3 months of making lifestyle changes. Sulfonylurea may be used if metformin cannot be tolerated. 1-4 Only add another medicine if target blood glucose levels are not achieved after titrating metformin (or a sulfonylurea) to the highest tolerated dose. 1,2 Always check and address other factors that may interfere with control before adding a second or third glucose-lowering medicine e.g. poor self-management

2019 National Prescribing Service Limited (Australia)

189. Second-line Drug Therapy for Patients with Type 2 Diabetes

KP National Heart Failure Lead KP Southern California Heart Failure Lead Reference: 1. Davies MJ, D’Alessio, DA, Fradkin, J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Oct 4. (...) Second-line Drug Therapy for Patients with Type 2 Diabetes Second-line drug therapy for patients with Type 2 Diabetes A Consensus Statement from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group November 19, 2018 The Kaiser Permanente ICVH group is aware of the new treatment recommendations published in the American Diabetes Association’s (ADA) Management of Hyperglycemia in Type 2 Diabetes 2018 Consensus Report. The ADA places newer diabetic medications

2019 Kaiser Permanente National Guideline Program

190. Minimed 670g - for the management of type 1 diabetes mellitus

Minimed 670g - for the management of type 1 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following (...) table describes post-licensing activity for the . For more information on the type of information found in PLATs, please refer to the For additional information about the medical device application process, refer to the . Licence Number: Post-Licensing Activity Table (PLAT) Activity/Application Type, Application Number Date Submitted Decision and Date Summary of Activities 1 What was approved? Application Milestones: Application Milestone Date For additional information about the medical device

2019 Health Canada - Drug and Health Product Register

191. Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease

Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Kaiser Permanente Research Affiliates Evidence-based Practice Center Corinne Evans, MPP; Nicholas Emptage, MAE; Megan Rushkin, MPH; and Jennifer S. Lin, MD, MCR Summary Question 1. In persons (...) with type 2 diabetes with or without known atherosclerotic cardiovascular disease (ASCVD) who cannot attain adequate glucose control with metformin, what is the benefit of GLP-1 agonists or SGLT-2 inhibitors on cardiovascular morbidity and mortality? • Evidence of benefit in persons with known ASCVD on cardiovascular disease (CVD) outcomes, CVD mortality and all-cause mortality (ACM) o Based on limited evidence in persons without ASCVD, no evidence of benefit on CVD outcomes • Presumed class effect

2019 Kaiser Permanente National Guideline Program

192. Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

... - PRESIDENTS AND STAFF - REFERENCES . - APPENDIX 1 Author Relationships With Industry and Other Entities (Relevant)—2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes .. - APPENDIX 2 Peer Reviewer Information .. - APPENDIX 3 Abbreviations .. - PREFACE The American College of Cardiology (ACC) develops a wide range of policy documents to provide members with guidance on clinical topics. Although Clinical Practice Guidelines remain (...) the leading cause of morbidity and mor- tality in patients with type 2 diabetes (T2D) (1).Overthat time, the prevalence of T2D has increased, while the excess risk of adverse CV events in patients with T2D (compared with patients without diabetes) has remained largely unchanged (2). Accordingly, the development of treatment strategies to improve CV outcomes in this vulnerable patient population remains a major priority. Diabetes is typically thought of as a disease of elevated blood glucose (3). Although

2019 American College of Cardiology

193. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA Full Text available with Trip Pro

with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease.Participants in 27 countries with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease were randomized 1:1 to receive once daily oral linagliptin 5 mg (...) Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes

2019 EvidenceUpdates

194. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes Full Text available with Trip Pro

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monotherapy.This

2019 EvidenceUpdates

195. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial Full Text available with Trip Pro

, we recruited patients with type 2 diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], and supportive periodontal therapy every 3 months until (...) Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial Chronic inflammation is believed to be a major mechanism underlying the pathophysiology of type 2 diabetes. Periodontitis is a cause of systemic inflammation. We aimed to assess the effects of periodontal treatment on glycaemic control in people with type 2 diabetes.In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial

2019 EvidenceUpdates

196. Optimal Insulin Correction Factor in Post-High-Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Full Text available with Trip Pro

Optimal Insulin Correction Factor in Post-High-Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Postexercise hyperglycemia, following high-intensity interval training (HIIT) in patients with type 1 diabetes (T1D), is largely underrecognized by the clinical community and generally undertreated. The aim of this study was to compare four multipliers of an individual's insulin correction factor (ICF) to treat post-HIIT hyperglycemia.The FIT study had a randomized (...) the 100 and 150% corrections were more effective than the 50% correction (P < 0.01 and P < 0.001, respectively) but were not different from each other. Hypoglycemia was rare.In post-HIIT hyperglycemia, correction based on a patient's usual ICF is safe and effective. Optimal PG reduction, with minimal hypoglycemia, occurred in the 100 and 150% correction arms.© 2018 by the American Diabetes Association.

2019 EvidenceUpdates

197. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study Full Text available with Trip Pro

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine.Eligible patients had inadequately controlled type 2 diabetes on metformin (≥1500 mg/d) in combination with a dipeptidyl (...) in hypoglycaemia. ClinicalTrials.gov Identifier: NCT02738879.© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2019 EvidenceUpdates

198. Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross-over trial Full Text available with Trip Pro

Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross-over trial The primary aim of this study was to investigate whether ascorbic acid (AA) supplementation improves postprandial glucose responses under free-living conditions in individuals with type 2 diabetes. A secondary aim was to investigate the effect of AA supplementation on blood pressure.A total of 31 individuals with type 2 diabetes (26 (...) pressures and in a specific fraction of free plasma F2 -isoprostanes (-47 pg/mL) as compared to placebo.Individuals with type 2 diabetes experienced improved postprandial and 24-hour glycaemia and decreased BP after 4 months of AA supplementation as compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and BP control in individuals with type 2 diabetes.© 2018 John Wiley & Sons Ltd.

2019 EvidenceUpdates

199. The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis (Abstract)

The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis The role of intensive glucose control in people with type 2 diabetes and pre-existing cardiovascular disease (CVD) is controversial. The aim of this systematic review and meta-analysis was to determine in a subset of people with type 2 diabetes and pre-existing CVD, the CV effect of intensive glucose control versus standard (...) of care. We searched Medline, the Cochrane library, EMBASE and the National Institutes of Health Trial registration database for randomized controlled trials that evaluated the effect of intensive glucose control versus standard glucose control in people with type 2 diabetes on incident CVD. Data were extracted using a structured form. When data were not available in the publications, authors were contacted. Eight trials involving 8339 participants were included. Among adults with type 2 diabetes

2019 EvidenceUpdates

200. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Full Text available with Trip Pro

Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular (...) , fasting laboratories after overnight glycemic control, and insulin sensitivity by hyperinsulinemic-euglycemic clamp (glucose infusion rate/insulin). Adolescents with T1DM were randomized 1:1 to 3 months of 2000 mg metformin or placebo daily, after which baseline measures were repeated.Forty-eight adolescents with T1DM who were 12 to 21 years of age (40% body mass index [BMI] ≥90th percentile; 56% female) and 24 nondiabetic control participants of similar age, BMI, and sex distribution were enrolled

2019 EvidenceUpdates